Pilot study of FPPRGD2 for imaging α(v)β(3) integrin--how integral are integrins?
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 21697304.
- Also identified by DOI 10.1148/radiol.11110740 and PMC identifier 3135879.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mittra et al (1) describe a new positron emission tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropionyl labeled PEGylated dimeric RGD peptide (FPPRGD2), a marker of α(v)β(3) integrin expression, which they tested in fi ve healthy volunteers. No adverse events were encountered, and the biodistribution suggested both a renal and a hepatobiliary excretory route. This early safety testing paves the way for future studies of patients with cancer who are undergoing antiangiogenic therapies. (18)F-FPPRGD2 represents one of several integrin imaging agents that are moving closer to clinical reality.
Medical subject headings
- Fluorine Radioisotopes
- Integrin alphaVbeta3
- Oligopeptides
- Positron-Emission Tomography